The Future of Early-Stage NSCLC Treatment: Updates on Neoadjuvant ImmunotherapyAn expert-led webinar designed to address the critical need for education about the potential future of neoadjuvant therapy for early-stage NSCLCCME: 1.0
Optimizing Outcomes in Newly Diagnosed Multiple Myeloma: Integrating Anti-CD38 Monoclonal Antibody Therapy Into Clinical PracticeIDENTIFY patients with newly diagnosed MM for whom treatment with an anti-CD38 monoclonal antibody-based therapeutic regimen would be appropriate CME: 0.5
Understanding the Unique Role of HER3 in OncogenesisExplore the clinical evidence surrounding the role of HER3 in various tumor types. CME: 0.75
Keeping an Eye Out: Emerging Trends in the Management of Metastatic Uveal MelanomaOutline how new or emerging options may fit into existing treatment algorithms for patients with uveal melanoma. CME: 0.75
Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes. CME: 1.0
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLLReview patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies CME: 1.5
Burst Expert Illustrations and Commentaries™: Visualizing Gene Therapy Approaches in Hemophilia AAssess the severity of hemophilia A according to clinical presentation and results of factor assays CME: 0.25
Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTPReview diagnostic challenges that are specific to acquired, immune-mediated TTP (thrombotic thrombocytopenic purpura ) CME: 0.75